A New Drug to Attack Aggressive Prostate Cancers
National Institutes of Health
The Institute of Cancer Research, in London, has reported that “Men with aggressive prostate cancer that has stopped responding to conventional treatment could potentially benefit from a new class of cancer drug designed to overcome drug resistance.”
The new drugs, Hsp90 inhibitors, target and then deactivate a mechanism prostate cancer cells use to evade the effects of standard treatment. The drugs are ready for clinical trial. Study Co-leader Professor Johann de Bono, Professor of Experimental Cancer Medicine at the ICR said, “I am excited that our work suggests they could also benefit men with prostate cancer who have otherwise run out of treatment options.”
Tags: cancer, biomedical engineering, chemistry, hormone treatment.
